The transient invigoration of exhausted CD8+ T cells to potent tumor-reactive cells has been achieved through the combination of anti-PD-1 therapy with PEGylated IL-10, leading to the expansion of a rare population of LAG-3+ PD-1+ CD8+ T cells that positively correlates with clinical response (65). This evidence concerns the gene CD8A and neoplasm.